NYSE:NUVB Nuvation Bio Q2 2026 Earnings Report $5.84 +0.03 (+0.50%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$5.82 -0.01 (-0.24%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nuvation Bio EPS ResultsActual EPSN/AConsensus EPS -$0.15Beat/MissN/AOne Year Ago EPSN/ANuvation Bio Revenue ResultsActual RevenueN/AExpected Revenue$26.88 millionBeat/MissN/AYoY Revenue GrowthN/ANuvation Bio Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Nuvation Bio Earnings HeadlinesCan Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level?45 minutes ago | finance.yahoo.comNuvation Bio (NYSE:NUVB) Price Target Raised to $13.00 at Truist FinancialJuly 7, 2026 | americanbankingnews.comThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline because the information inside is too sensitive to leave up indefinitely. Inside the remaining copies is the executive order Trump can sign tomorrow, the same legal authority FDR used in 1934 to move billions in wealth overnight, and exactly how to position before it happens.July 13 at 1:00 AM | American Alternative (Ad)Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes OfferingJuly 6, 2026 | prnewswire.comIs Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?July 2, 2026 | finance.yahoo.comNuvation Bio Issues Convertible Notes, Retires Secured DebtJune 30, 2026 | tipranks.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB) is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies. The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors. Nuvation Bio emphasizes a translational science approach, using biomarker strategies and patient-selection criteria to guide trial design and optimize the likelihood of clinical success. Its scientists leverage process chemistry expertise to streamline manufacturing and ensure scalable drug supply. Headquartered in New York, Nuvation Bio conducts global development activities through collaborations with leading academic centers, clinical research organizations, and commercial partners. The company’s leadership team brings extensive experience in drug discovery, translational research, and clinical development from both large pharmaceutical companies and emerging biotechnology firms. Adopting a capital-efficient operating model, Nuvation Bio balances in-house capabilities with strategic outsourcing to manage costs and accelerate timelines. With its focused pipeline and integrated development infrastructure, the company seeks to address critical unmet needs in oncology and advance novel therapies that have the potential to improve patient outcomes.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real Profit Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
